![Michael Dunn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Dunn
President bij
CALCIMEDICA, INC.
Vermogen: 2 352 $ op 31-07-2026
Profiel
Michael J.
Dunn is currently Director at Arisan Therapeutics, Inc., President & Chief Operating Officer at CalciMedica Subsidiary, Inc. since 2013, and President & Chief Operating Officer at CalciMedica, Inc. since 2014, with the title updated in 2020.
Former roles include Director at Aegea Biotechnologies, Inc. from 2012 to 2017; Vice President-Business Development at Sibia Neurosciences, Inc.; Chief Business Officer & Vice President at Monogram Biosciences, Inc.; SVP-Corporate Development & Business Development at Biocept, Inc. from 2011 to 2013; Chief Business Officer & Vice President at ACLARA Biosciences, Inc. from 2003 to 2004; Vice President-Business Development at Aurora Biosciences Corp.
from 1998 to 2002; and Chief Business Officer & Vice President at ActivX Biosciences, Inc. from 2002 to 2003.
Education includes undergraduate studies at The University of Chicago and an MBA from the University of San Diego.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CALCIMEDICA, INC. 0,01% | 24-06-2025 | 2.352 ( 0,01% ) | 2 352 $ | 31-07-2026 |
Actieve functies van Michael Dunn
| Bedrijven | Functie | Begin |
|---|---|---|
| CALCIMEDICA, INC. | President | 01-01-2014 |
Arisan Therapeutics, Inc.
 Arisan Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutic for the treatment of neglected and emerging infectious diseases | Directeur/Bestuurslid | - |
Eerdere bekende functies van Michael Dunn
| Bedrijven | Functie | Einde |
|---|---|---|
Aegea Biotechnologies, Inc.
 Aegea Biotechnologies, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | Directeur/Bestuurslid | 01-01-2017 |
| BIOCEPT, INC. | Corporate Officer/Principal | - |
ACLARA Biosciences, Inc.
 ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology Discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic and oncologic diseases | Corporate Officer/Principal | 01-12-2004 |
ActivX Biosciences, Inc.
 ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops drug molecule for hematology, oncology, metabolic and inflammatory diseases | Corporate Officer/Principal | 01-04-2003 |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Designs and develops proprietary drug discovery systems, services and technologies | Corporate Officer/Principal | 01-03-2002 |
Opleiding van Michael Dunn
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
34
Eerstegraads connecties
12
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 12 |
|---|---|
Sibia Neurosciences, Inc.
 Sibia Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, small molecule therapeutics for disorders of the nervous system | Health Technology |
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Designs and develops proprietary drug discovery systems, services and technologies | Health Technology |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology Discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic and oncologic diseases | Health Technology |
Monogram Biosciences, Inc.
 Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services for HIV treatment | Commercial Services |
Biocept, Inc.
 Biocept, Inc. Medical/Nursing ServicesHealth Services Develops and performs clinical laboratory tests to detection & analysis of tumor cells and cell-free DNA from cerebrospinal fluid | Health Services |
CalciMedica Subsidiary, Inc.
 CalciMedica Subsidiary, Inc. BiotechnologyHealth Technology Engages in drug development | Health Technology |
Arisan Therapeutics, Inc.
Arisan Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutic for the treatment of neglected and emerging infectious diseases | Health Technology |
ActivX Biosciences, Inc.
ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops drug molecule for hematology, oncology, metabolic and inflammatory diseases | Health Technology |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of San Diego
 University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aegea Biotechnologies, Inc.
Aegea Biotechnologies, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | Health Services |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
